 "Sun Pharma Q4 profit declines 37% to Rs 399 cr on one-time exceptional loss")
Pharma major Sun Pharmaceutical Industries on Wednesday reported a 37.12 per cent decline in its consolidated net profit to Rs 399.84 crore for the quarter ended March 2020, mainly on account of one-time exceptional loss.
The company had posted a net profit of Rs 635.88 crore in the same period previous fiscal, Sun Pharma said in a BSE filing.
Consolidated revenue from operations stood at Rs 8,184.94 crore for the quarter under consideration as against Rs 7,163.92 crore in the same period a year ago,it added.
The company had a one-time exceptional loss of Rs 260.64 crore in the quarter ended March 2020, the filing said.
For the fiscal ended March 2020, the net profit of the company was at Rs 3,764.93 crore as against Rs 2,665.42 crore in the previous fiscal, Sun Pharma said.
ALSO READ: First Covid-19 vaccine to reach phase-1 trial is safe, say researchers
The revenue from operations for the fiscal ended March this year stood at Rs 32,837.50 crore. It was Rs 29,065.91 crore the year-ago fiscal, it added.
The board has recommended payment of dividend of Re 1 per equity share of Re 1 each for the year ended March 31, 2020, Sun Pharma said.
Shares of Sun Pharmaceutical Industries were closed at Rs 450.55 per scrip on the BSE, down1.85 per cent from its previous close.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app